Predicting disease flare and treatment response in inflammatory bowel disease

Status	Finished
Effective start/end date	1/11/19 → 31/10/24

Tofacitinib versus Vedolizumab Among Bio-naïve Patients with Ulcerative Colitis: A Real-World Propensity-Weighted Comparison
Gros, B., Constantine-Cooke, N., Kennedy, J., Elford, A. T., O’hare, C., Noble, C., Jones, G-R., Arnott, I. D., Lees, C. W. & Plevris, N., 3 Dec 2024, (Accepted/In press) In: Journal of Crohn's and Colitis.
Research output: Contribution to journal › Article › peer-review
Long-term outcomes and predictors of vedolizumab persistence in ulcerative colitis
Gros, B., Ross, H., Nwabueze, M., Constantine-Cooke, N., Derikx, L. A. A. P., Lyons, M., O'Hare, C., Noble, C., Arnott, I. D., Jones, G-R., Lees, C. W. & Plevris, N., 30 Jul 2024, In: Therapeutic Advances in Gastroenterology. 17, 14 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort
Gros, B., Plevris, N., Constantine-Cooke, N., Lyons, M., O'Hare, C., Noble, C., Arnott, I. D., Jones, G-R., Lees, C. W. & Derikx, L. A. A. P., 1 Mar 2023, In: United European Gastroenterology Journal. 11, 2, p. 179-188 10 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File

Project Details